In the midst of economic uncertainties and fluctuating indices, the European market has been navigating challenges such as U.S. trade tariffs and monetary policy shifts, with major stock indexes showing mixed performances. Despite these hurdles, opportunities arise for discerning investors to identify undervalued stocks that may offer potential value in a volatile environment.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Telefonaktiebolaget LM Ericsson (OM:ERIC B) | SEK83.36 | SEK164.66 | 49.4% |
Fondia Oyj (HLSE:FONDIA) | €5.45 | €10.63 | 48.7% |
JOST Werke (XTRA:JST) | €50.00 | €98.51 | 49.2% |
Storytel (OM:STORY B) | SEK92.70 | SEK180.62 | 48.7% |
dormakaba Holding (SWX:DOKA) | CHF680.00 | CHF1358.27 | 49.9% |
Star7 (BIT:STAR7) | €6.20 | €12.36 | 49.8% |
Cint Group (OM:CINT) | SEK6.40 | SEK12.79 | 49.9% |
Neosperience (BIT:NSP) | €0.53 | €1.06 | 49.9% |
Cavotec (OM:CCC) | SEK17.35 | SEK34.07 | 49.1% |
Fodelia Oyj (HLSE:FODELIA) | €7.12 | €13.91 | 48.8% |
Click here to see the full list of 199 stocks from our Undervalued European Stocks Based On Cash Flows screener.
Let's uncover some gems from our specialized screener.
Overview: ASML Holding N.V. specializes in providing lithography solutions essential for semiconductor equipment systems, with a market capitalization of approximately €257.88 billion.
Operations: The company's revenue is primarily generated from its Semiconductor Equipment and Services segment, which accounted for €28.26 billion.
Estimated Discount To Fair Value: 15.7%
ASML Holding's recent strategic partnership with imec underscores its commitment to innovation and sustainability in the semiconductor industry. The stock trades at approximately €655.7, below its estimated fair value of €778.05, suggesting potential undervaluation based on cash flows. Despite insider selling, ASML is expected to achieve annual earnings growth of 15.4%, surpassing the Dutch market average, while maintaining a high return on equity forecasted at 45.9% over three years.
Overview: Airbus SE, along with its subsidiaries, is involved in the design, manufacture, and delivery of aeronautics and aerospace products, services, and solutions globally with a market cap of approximately €133.32 billion.
Operations: The company's revenue is primarily generated through its segments: Airbus Helicopters (€7.94 billion), Airbus Defence and Space (€12.08 billion), and Airbus, which includes Holding Function and Bank Activities (€50.65 billion).
Estimated Discount To Fair Value: 47.1%
Airbus is trading at €169.2, significantly below its estimated fair value of €319.77, highlighting potential undervaluation based on cash flows. Earnings have grown 42.2% annually over the past five years and are forecast to grow 17.3% per year, outpacing the French market's average growth rate. Recent regulatory approval in China for value-added telecom services could enhance revenue streams, while ongoing negotiations with Spirit AeroSystems may impact future operations and asset allocations in Belfast.
Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of approximately €5.61 billion.
Operations: The company's revenue is primarily derived from two segments: Ophthalmic Devices, including Surgical Ophthalmology, which contributes approximately €1.61 billion, and Microsurgery, which accounts for about €467.36 million.
Estimated Discount To Fair Value: 30.5%
Carl Zeiss Meditec is trading at €64.1, significantly below its estimated fair value of €92.21, suggesting undervaluation based on cash flows. Despite a decline in net income to €15.7 million from €37.4 million year-over-year, earnings are expected to grow over 20% annually, surpassing the German market's growth rate of 16.5%. Recent FDA approval for the MEL 90 excimer laser could bolster revenue through expanded offerings in U.S. refractive clinics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTAM:ASML ENXTPA:AIR and XTRA:AFX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.